智通财经APP获悉，诺华制药(NVS.US)预计，到 2030 年，经汇率调整后的销售额将增长 5%至 6%。这得益于其抗癌药物 Kisqali 和 Scemblix 的营收预期将达到更高水平。这家制药公司上调了 Kisqali(用于治疗一种常见的乳腺癌)的峰值销售额预测，从之前的 80 亿美元上调至至少 100 亿美元。对于白血病药物 Scemblix，诺华公司现在预计其峰值销售额至少为 40 亿美元，高于之前的至少 30 亿美元的预期。
该公司表示，其八款最具潜力的获批药物每款的潜在销售峰值都在 30 亿至 100 亿美元之间。
上个月，该公司以 120 亿美元的价格收购了Avidity Biosciences，以增加肌肉疾病治疗药物的候选产品，这是其为抵消现有产品(包括其心力衰竭药物Entresto)销售下滑而采取的更广泛举措的一部分。该公司曾表示，此次收购计划将使其 2024 至 2029 年的年销售额增长率预测提高到 6%，高于此前预期的 5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.